[Evaluation of postoperative immunochemotherapy in lung cancer].
A study of postoperative adjuvant chemotherapy according to cell type, combined with immunotherapy using PSK and OK-432 was conducted in 178 lung cancer patients who had undergone resection. BRM (PSK or OK-432) was selected by randomization. Chemotherapy was mainly performed with VCR, MMC, and MTX except for small cell carcinoma. Of the total number of lung cancer cases, 113 were evaluable. Four-year survival rates were 36.7% for the OK-432 group, 55.9% for the PSK group and 34.7% for the control group, with significant differences among these three groups. Survival rates for stage III showed significant differences between immunochemotherapy groups, (OK-432 group, PSK group) and the chemotherapy group. Postoperative administration of immunomodulators is therefore considered to contribute to the improved survival of patients in lung cancer.
D000230:Adenocarcinoma / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D000328:Adult; D000368:Aged; D001688:Biological Products / Q000627:therapeutic use*; D018288:Carcinoma, Small Cell / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000401:mortality / Q000601:surgery / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010844:Picibanil / Q000627:therapeutic use*; D011013:Pneumonectomy; D011184:Postoperative Period; D011379:Prognosis; D011509:Proteoglycans / Q000627:therapeutic use*; D011897:Random Allocation
D001688:Biological Products; D011509:Proteoglycans; D010844:Picibanil; C010770:polysaccharide-K